Food Allergy: Is It the Environment? Or Genetic? (AAN)

Price: FREE for members and non-members

Session recorded on February 14, 2023

Speaker: (Tina) Sayantani B. Sindher, MD, 
Director of the Clinical Translational Research Unit at Stanford University 

Family history is known to be a risk factor for the development of food allergy, however whether this is driven by genetics or environmental influence is not well understood. Topics discussed in this webinar will include the role of genetics and environment play in the risk of developing food allergy; the 6 D's of allergy prevention; and the link between early atopic dermatitis with development of subsequent food allergy.

Viewers can earn credit by completing the posttest questions.

This program is a collaboration between the American College of Allergy, Asthma and Immunology and the Allergy and Asthma Network.

Explore other archived clinical webinars here.

Accreditation
The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 1 AMA PRA Category 1 CreditTM.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Target Audience

Primary Care Providers
Pediatricians
Fellows-in-Training

Learning Objectives

Upon completion of this activity, learners should be able to:
1. Recognize the role of both genetics and environment on the risk of developing food allergy.
2. Describe the 6 D’s of allergy prevention.
3. Proactively manage atopic dermatitis in young infants and have a low threshold for referral to allergist given the link between early atopic dermatitis with development of subsequent food allergy.
 

Additional information
Disclosure: 

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months. Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing health care products used by or on patients. The ACCME does not consider providers of clinical service directly to patients to be Ineligible Companies. Examples of ineligible companies include: 
 
•    Advertising, marketing, or communication firms whose clients are ineligible companies
•    Bio-medical startups that have begun a governmental regulatory approval process
•    Compounding pharmacies that manufacture proprietary compounds
•    Device manufacturers or distributors
•    Diagnostic labs that sell proprietary products
•    Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
•    Manufacturers of health-related wearable products
•    Pharmaceutical companies or distributors
•    Pharmacy benefit managers
•    Reagent manufacturers or sellers
  
The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.

Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.

Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. All identified relevant financial relationships have been mitigated.

Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance
Course opens: 
02/15/2023
Course expires: 
12/31/2024
Rating: 
0

All relevant financial relationships have been mitigated.
The individuals listed below disclose the following financial relationships:

(Tina) Sayantani B. Sindher, MD
Advisor: Genentech, DBV Technologies

Additional information
Disclosure: 
As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months. The ACCME defines an “ineligible company” as companies whose primary business is producing, marketing, re-selling, or distributing health care goods or services, used by or on patients. Examples of such organizations include:

•    Advertising, marketing, or communication firms whose clients are ineligible companies
•    Bio-medical startups that have begun a governmental regulatory approval process
•    Compounding pharmacies that manufacture proprietary compounds
•    Device manufacturers or distributors
•    Diagnostic labs that sell proprietary products
•    Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
•    Manufacturers of health-related wearable products
•    Pharmaceutical companies or distributors
•    Pharmacy benefit managers
•    Reagent manufacturers or sellers

The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.

Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.

Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. All identified conflicts of interest have been mitigated.

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance
Please login or create an account to take this course.